Ashland Inc. logo

Ashland Inc.

ASH | NYSE
Chart Builder DCF Calculator
$69.11
+$0.05 (+0.07%)
Sep 21, 2026, 10:21 AM ET · Market open
+0.07%

Rating

Updated: Aug 25, 2026
41.9
Fundamentals Average
Market Sentiment Neutral
Moat None

Key Statistics

Market Data

Market Cap $3.16B
1D Range
68.63 69.99
52W Range
46.30 78.25

Valuation (TTM)

PE 61.12
PB 1.69
EV/EBITDA 11.73

Valuation (NTM)

Forward PE 15.98
Forward PEG 2.75
Price Target $78.71
Loading financial charts...

Profile

Ashland Inc. operates as a global supplier of specialized chemicals and additives. Its business activities are structured into four main divisions: Life Sciences; Personal Care & Household; Specialty ...

Employees 2,900
IPO Date Mar 16, 1980
Fiscal Year October - September

Latest News

Ashland Inc. (ASH) Analyst/Investor Day Transcript

3 days ago · seekingalpha.com

Ashland Inc. (ASH) Analyst/Investor Day Transcript
UPDATE - Major expansion of Ashland Sawmill announced

4 days ago · globenewswire.com

UPDATE - Major expansion of Ashland Sawmill announced
Major expansion of Ashland Sawmill announced

5 days ago · globenewswire.com

Major expansion of Ashland Sawmill announced
Here's Why You Should Retain ASH Stock in Your Portfolio Now

5 days ago · zacks.com

Here's Why You Should Retain ASH Stock in Your Portfolio Now
Ashland Innovation Day to be held September 17, 2026

7 days ago · globenewswire.com

Ashland Innovation Day to be held September 17, 2026
Ashland to host Innovation Day for analysts and investors

21 days ago · globenewswire.com

Ashland to host Innovation Day for analysts and investors
Ashland (ASH) Up 2% Since Last Earnings Report: Can It Continue?

25 days ago · zacks.com

Ashland (ASH) Up 2% Since Last Earnings Report: Can It Continue?
ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth

27 days ago · zacks.com

ASH Launches Permexa Sodium Caprate to Support Oral Biologics Growth
Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

28 days ago · globenewswire.com

Ashland advances high-growth oral biologics delivery applications with launch of permexa™ sodium caprate

Earnings

Next Earnings
Nov 3, 2026
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
9
Consensus
Buy
Price Target
$78
Upside
+12.86%
Buy (6)
Hold (0)
Sell (0)
Analyst Details

© 2026 bestshares.com. All rights reserved.